1996～ 1999年我科应用米托蒽醌联合 VP16治疗难治性白血病 11例 ,疗效满意 ,现报道如下。1　资料与方法1.1　病例选择　根据 Hiddemann提出的标准 [1 ] ,经标准的诱导化疗及缓解后治疗的患者出现下列之一项 ,称之为难治性白血病 :1经标准诱导化疗方案化疗 2个疗程不缓解者 ;2 From 1996 to 1999, 11 patients with refractory leukemia were treated with mitoxantrone and VP16 in our department. The curative effect was satisfactory and is reported as follows. 1 Materials and methods 1.1 Case selection According to the criteria proposed by Hiddemann [1], patients undergoing standard induction chemotherapy and post-remission therapy have one of the following conditions, referred to as refractory leukemia: 1 2 courses of chemotherapy by standard induction chemotherapy regimen Not relieved; 2